Everything below concerns incretin. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-02-18. Numbers and descriptions here follow the published literature rather than marketing material.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
| Property | Value | Notes |
|---|---|---|
| Molecular class | 31-amino-acid peptide | Modified glucagon-like peptide-1 analogue |
| Molecular mass | approximately 4114 Da | Calculated for the free peptide backbone |
| Appearance | white to off-white powder | Typical of purified lyophilised peptide batches |
| Solubility class | freely soluble in water | Aqueous solubility improves at slightly alkaline pH |
| Typical storage | -20 degrees Celsius, dry, dark | Protect from repeated freeze-thaw cycles |
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
As a peptide, semaglutide is sensitive to conditions that break amide bonds or modify side chains. Deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation are the main degradation routes described in published stability work. Rate depends strongly on pH, buffer species, ionic strength, temperature and exposure to light. Formulators therefore choose a defined solution pH and often add excipients such as phosphate buffer, propylene glycol and phenol, each of which plays a separate role in pH control, tonicity or preservation.
Storage guidance for the finished injectable product distinguishes the unused state from the in-use state. Before first use, pens are kept refrigerated between 2 and 8 degrees Celsius, protected from light, and never frozen, since freezing can disrupt the peptide or the device. After first use, label instructions in several markets permit storage at room temperature up to about 30 degrees Celsius for a limited number of days. Solid research-grade material is normally held at or below minus 20 degrees Celsius, often with desiccant, and allowed to equilibrate before opening.
Quantification and purity assessment rely on separation methods coupled to optical or mass detection. Reversed-phase high-performance liquid chromatography resolves the intact peptide from related impurities and is the standard assay technique. Size-exclusion chromatography measures aggregates, while ion-exchange chromatography separates charge variants produced by deamidation. Mass spectrometry confirms identity and detects mass shifts of a few daltons. In biological matrices, liquid chromatography with tandem mass spectrometry is often used because immunoassays can cross-react with endogenous GLP-1 or with circulating fragments.
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
关于降解产物的免疫原性风险，文献中仍有讨论空间。体外聚集水平与临床免疫反应之间的定量关系尚未确立。多数公开研究只报告理化指标，缺少长期随访的对应数据。这一问题在生物类似物比对中尤其受到关注。
市售注射用制剂通常要求在二至八摄氏度冷藏保存，并避免光照与冻结。部分多剂量笔在首次使用后允许在不超过三十摄氏度的环境中存放有限周数，具体期限由辅料与防腐剂体系决定。反复冻融会促进肽链聚集并改变可见颗粒计数，因此应予避免。冻干粉末在干燥、避光、低温条件下更为稳定。溶液配制后宜使用低吸附容器，以减少肽类在塑料或玻璃表面的损失。
===== Other names in the Western world ===== In the last decades, two new important terminologies emerged. Both are commonly used in the Western world in neoshamanic, recreative or pharmaceutical contexts to address ayahuasca-like substances created without the traditional botanical species, due to it being expensive and/or hard to find in these countries. These concepts are surrounded by some controversies involving ethnobotany, patents, commodification and biopiracy:
The ease with which our potatoes lend themselves to all sorts of stews gave me the idea of composing a meal of them, to which I invited several amateurs; and at the risk of being thought to be afflicted with potato mania, I will end this review by describing it: it was a dinner. We were first served two soups, one of mashed potatoes from our roots, the other of a fatty broth, in which the potato bread simmered quite well without crumbling; then came a matelote followed by a dish in white sauce, then another in maitre d'hôtel, and finally a fifth in roux. The second service consisted of five other dishes not less good than the first; first a pâté, a frying, a salad, fritters, and the economic cake of which I gave the recipe; the remainder of the meal was not very extensive, but delicate and good; a cheese, a pot of jam, a plate of cookie, another of tarts, and finally a brioche also of potatoes, made up the dessert; after that we had the coffee, also described above. There were two kinds of bread; the one mixed with potato pulp and wheat flour, fairly represented soft bread; the second, made of potato pulp, with their starch, bore the name of firm dough bread; I would have wished that fermentation had put me in a position to make a drink of our roots, to fully satisfy my guests, and to say with foundation: "Do you like potatoes, we have put them everywhere." Every one was cheerful; and if potatoes are drowsy, they produce on us a very opposite effect.
=== In-N-Out Burgers Foundation === In-N-Out Burgers Foundation (known from March 13–April 14 1995 as The In-N-Out Foundation) is a 501(c)(3) nonprofit organization founded on March 13, 1995, and classified as a "Human Services: Fund Raising & Fund Distribution" organization under the NTEE system. Based in Irvine, California, the foundation "supports organizations that provide residential treatment, emergency shelter, foster care, and early intervention for children in need". Its grant-making activities are restricted to eligible nonprofit groups that are located or provide services in areas where In-N-Out has a presence. Consequently, grant proposals are only accepted from applicants in a limited number of counties in Arizona, California, Nevada, Utah, Texas. In 2010, the most recent year for which financial reporting is publicly available (and before the opening of the company's Texas locations), the foundation contributed $1,545,250 to 231 grantees in Arizona, California, Nevada, Utah. Grant-making is funded through donor contributions and In-N-Out-sponsored fundraisers; typical grants are between $2,000 and $20,000.
== Use in cell culture == Together with other major components of the ECM, such as collagens and fibronectin, laminins have been used to enhance mammalian cell culture, especially in the case of pluripotent stem cells, as well as some primary cell cultures, which can be difficult to propagate on other substrates. Two types of naturally sourced laminins are commercially available: Laminin-111, extracted from mouse sarcomas, and laminin mixtures from human placenta, which may primarily correspond to laminin-211, 411, or 511, depending on the provider. The various laminin paralogs are practically impossible to isolate from tissues in pure form due to extensive cross-linking and the need for harsh extraction conditions, such as proteolytic enzymes or low pH, that cause degradation. Therefore, recombinant laminins have been produced since the year 2000. This made it possible to test if laminins could have a significant role in vitro as they have in the human body. In 2008, two groups independently showed that mouse embryonic stem cells can be grown for months on top of recombinant laminin-511. Later, Rodin et al. showed that recombinant laminin-511 can be used to create a xeno-free and defined cell culture environment to culture human pluripotent ES cells and human iPS cells.
Sources: en.wikipedia.org
=== May === 3 May – Astronomers from the University of Warwick report 118 new confirmed exoplanets, with a further 2,000 "high-quality" candidates, detected using machine learning applied to data from NASA's Transiting Exoplanet Survey Satellite (TESS). 4 May The discovery of a thin atmosphere on the trans-Neptunian object (612533) 2002 XV93 is announced. A study published in Communications Sustainability finds that utility-scale solar power and wind power generally provide greater climate and public health benefits per dollar than direct air capture (DAC), based on modelling across 22 U.S. grid regions through 2050. The authors conclude that DAC becomes competitive mainly under a breakthrough scenario in which energy use falls from 5,500 to 800 kWh and cost from US$1,000 to US$100 per tonne of CO2 captured. A meta-analysis of over 20,000 participants concludes that drugs targeting amyloid beta peptides do not meaningfully slow progression of Alzheimer's disease. 6 May – A study in npj Space Exploration, using radar data from India's Chandrayaan-2 orbiter, reports strong evidence for subsurface water ice in four doubly-shadowed craters near the lunar south pole. 8 May – A study published in Aging Cell reports that the exceptional-longevity-associated APOE ε2 allele is associated with enhanced DNA-damage response and repair pathways in human neurons.
=== Laboratory testing === Because newborn screening programs test for a number of conditions, a number of laboratorial methodologies are used, as well as bedside testing for hearing loss using evoked auditory potentials and congenital heart defects using pulse oximetry. In the early 1960s Newborn screening started out using simple bacterial inhibition assays to screen for a single disorder, starting with phenylketonuria. With this testing methodology, newborn screening required one test to detect one condition. As mass spectrometry became more widely available, the technology allowed rapid determination of a number of acylcarnitines and amino acids from a single dried blood spot. This increased the number of conditions that could be detected by newborn screening. Enzyme assays are used to screen for galactosemia and biotinidase deficiency. Immunoassays measure thyroid hormones for the diagnosis of congenital hypothyroidism and 17α-hydroxyprogesterone for the diagnosis of congenital adrenal hyperplasia. Molecular techniques are used for the diagnosis of cystic fibrosis and severe combined immunodeficiency. As of 2023, numerous initiatives using next generation sequencing (NGS) have been announced worldwide including the Genomic Uniform-screening Against Rare Diseases in All Newborns (GUARDIAN study), BeginNGS and Early Check in the USA, BabyScreen+ in Australia, Generation Study by Genomics England, and Screen4Care, Baby Detect in Belgium and PERIGENOMED in France.
=== Vaccine Impact Modelling Consortium === The Vaccine Impact Modelling Consortium (VMIC) consists of mathematical models of diseases to analyze the impact of Gavi's vaccines, mainly in terms of deaths averted and disability-adjusted life year loss prevented, and to help Gavi come up with ways to maximize the impact for a given amount of resources. It consists of several different groups of modellers working independently. In 2026, the VMIC published an analysis on the impact Gavi's vaccination programmes against 14 vaccine-preventable diseases across 117 low- and middle-income families. In terms of lives saved per 1000 vaccinations, HPV (11.24), measles (6.09), HepB (5.00), and malaria (2.78) were found to be the most imapctful. In terms of DALY-loss prevented per 1000 vaccinations, HPV (523.04), measles (411.01), malaria (203.04), and Hib (150.37) were the most impactful. This analysis describes the effect of increasing vaccination on top of an existing level of coverage and disease burden, so vaccinating against a disease that has already achieved herd immunity can appear less impactful.
Sources: en.wikipedia.org
== H == Hajos–Parrish–Eder–Sauer–Wiechert reaction Haller–Bauer reaction Haloform reaction Halogen addition reaction Halohydrin formation reaction Hammick reaction Hammond principle or Hammond postulate Hantzsch pyrrole synthesis Hantzsch dihydropyridine synthesis, Hantzsch pyridine synthesis Hantzsch pyridine synthesis, Gattermann–Skita synthesis, Guareschi–Thorpe condensation, Knoevenagel–Fries modification Hantzsch–Collidin synthesis Harries ozonolysis Haworth methylation Haworth synthesis Hay coupling Hayashi rearrangement Heck reaction Hegedus indole synthesis Helferich method Hell–Volhard–Zelinsky halogenation Hemetsberger indole synthesis Hemetsberger–Knittel synthesis Henkel reaction, Raecke process, Henkel process Henry reaction, Kamlet reaction Herz reaction, Herz compounds Herzig–Meyer alkimide group determination Heumann indigo synthesis Hiyama coupling Hydration reaction Hydroamination Hydrodesulfurization Hydrogenolysis Hydrosilylation Hinsberg indole synthesis Hinsberg oxindole synthesis Hinsberg reaction Hinsberg separation Hinsberg sulfone synthesis Hirao coupling Hoch–Campbell ethylenimine synthesis Hock rearrangement Hofmann bromamide reaction Hofmann degradation, Exhaustive methylation Hofmann elimination Hofmann Isonitrile synthesis, Carbylamine reaction Hofmann product Hofmann rearrangement Hofmann–Löffler reaction, Löffler–Freytag reaction, Hofmann–Löffler–Freytag reaction Hofmann–Martius rearrangement Hofmann's rule Hofmann–Sand reaction Homo rearrangement of steroids Hooker reaction Horner–Wadsworth–Emmons reaction Hoesch reaction Hosomi–Sakurai reaction Houben–Fischer synthesis Hudlicky fluorination Huisgen cycloaddition Hunsdiecker reaction, Hunsdiecker–Borodin reaction Hurd-Mori 1,2,3-thiadiazole synthesis Hurtley reaction Hydroboration Hydrocarbon cracking Hydrohalogenation
=== TNXB (functional gene) === The TNXB gene localizes to the major histocompatibility complex (MHC class III) region on chromosome 6. The structure of this gene is unusual in that it overlaps the CREBL1 and CYP21A2 genes at its 5' and 3' ends, respectively.
== Interactions == Buspirone has been shown in vitro to be metabolized by the enzyme CYP3A4. This finding is consistent with the in vivo interactions observed between buspirone and these inhibitors or inducers of cytochrome P450 3A4 (CYP3A4), among others:
Sources: en.wikipedia.org
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.
No. It shares high sequence identity but carries non-natural modifications that alter its stability and clearance. The naturally occurring hormone is broken down within minutes, while the synthetic analogue circulates far longer.
Attachment to serum albumin reduces renal filtration of the peptide and shields it from enzymatic breakdown. The consequence is a much longer interval between administrations than unmodified peptides allow. The precise contribution of binding affinity to overall duration is still being quantified.
Native GLP-1 is degraded within minutes by circulating enzymes. The synthetic version carries substitutions at positions that block enzymatic cleavage, plus a fatty acid side chain that promotes albumin binding. These two changes together extend circulation time from minutes to roughly a week.